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Abstract
Obesity and associated metabolic disturbances, such as increased circulating fatty acids cause prolonged low grade
activation of inflammatory signaling pathways in liver, skeletal muscle, adipose tissue and even in the CNS. Activation of
inflammatory pathways in turn impairs insulin signaling, ultimately leading to obesity-associated type 2 diabetes mellitus.
Conventional JNK-1 knock out mice are protected from high fat diet-induced insulin resistance, characterizing JNK-1-
inhibition as a potential approach to improve glucose metabolism in obese patients. However, the cell type-specific role of
elevated JNK-1 signaling as present during the course of obesity has not been fully elucidated yet. To investigate the
functional contribution of altered JNK-1 activation in skeletal muscle, we have generated a ROSA26 insertion mouse strain
allowing for Cre-activatable expression of a JNK-1 constitutive active construct (JNKC). To examine the consequence of
skeletal muscle-restricted JNK-1 overactivation in the development of insulin resistance and glucose metabolism, JNKC mice
were crossed to Mck-Cre mice yielding JNKSM-C mice. However, despite increased muscle-specific JNK activation, energy
homeostasis and glucose metabolism in JNKSM-C mice remained largely unaltered compared to controls. In line with these
findings, obese mice with skeletal muscle specific disruption of JNK-1, did not affect energy and glucose homeostasis. These
experiments indicate that JNK-1 activation in skeletal muscle does not account for the major effects on diet-induced, JNK-1-
mediated deterioration of insulin action and points towards a so far underappreciated role of JNK-1 in other tissues than
skeletal muscle during the development of obesity-associated insulin resistance.
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Introduction
The increasing prevalence of obesity in the population of
developed countries represents a serious health problem, since
obesity is a major risk factor for the development of insulin
resistance, hyperglycemia, and metabolic syndrome. It is therefore
important to understand the molecular mechanism that accounts
for obesity-induced insulin resistance. Weight gain during the
course of obesity induces low grade chronic inflammation in white
adipose tissue (WAT) and liver leading to the release of pro-
inflammatory cytokines such as TNF-a into circulation [1]. TNF-a
inhibits insulin action in classical insulin target tissues such as
skeletal muscle, liver and adipose cells, thereby resulting in
impaired glucose homeostasis [2,3]. Here, TNF-stimulated acti-
vation of the cJun N-terminal kinase (JNK) and inhibitor of kB
kinase (IKK) signaling pathways inhibit insulin action in a tissue-
specific manner [2,4–6]. Moreover, JNK activation mediates
insulin resistance by other activators such as free fatty acids and
ER stress, both of which are elevated during the course of obesity
[7,8]. JNK activation leads to inhibitory serine phosphorylation of
insulin receptor substrate (IRS) proteins inhibiting insulin signaling
thus causing insulin resistance and ultimately contributing to the
development of type 2 diabetes mellitus [9].
JNKs are expressed by three different genes, JNK-1, -2 and -3,
all of which generate various JNK-isoforms by alternative splicing
mechanisms [10]. JNK-1 and -2 are ubiquitously expressed, while
JNK-3 expression is restricted mainly to brain and heart [11].
Recent studies identified JNK-1 as the major isoform contributing
to the development of obesity-associated insulin resistance, since
mouse mutants deficient for JNK-1 but not those for JNK-2 are
largely protected from the development of obesity and obesity-
associated insulin resistance in both diet- and genetically-induced
obesity models [12,13]. However, the tissue-specific contribution
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of JNK-1-deficiency to the development of obesity-associated
insulin resistance in vivo is poorly understood. While adipose-tissue-
specific JNK-1-deficiency confers some protection to obesity-
associated insulin resistance [14], analyses of the contribution of
JNK-1-action in the hematopoetic system using bone marrow
transplantation have yielded conflicting results [15,16]. On the
other hand, myeloid lineage-cell-specific disruption of JNK-1
failed to protect from obesity-associated insulin resistance, ruling
out a major contribution of macrophages to this phenomenon
[14]. More recently, skeletal muscle-specific JNK-1 disruption
reported by Sabio and colleagues revealed a potential role of JNK-
1 signaling in the control of systemic insulin sensitivity in high fat
diet-induced obesity [17]. Specifically, muscle-specific JNK-1-
deficiency left body weight gain and glucose tolerance unaltered
during the course of obesity, but ameliorated insulin sensitivity and
insulin-stimulated AKT phosphorylation in liver and WAT but
not in the JNK-1-deficient muscle [17]. Interestingly, another
study using disruption of JNK-1 in hepatocytes demonstrated that
hepatic JNK-1-signaling in lean mice is required to prevent the
development of steatosis, while in diet-induced obese mice, JNK-1-
deficiency was unable to further aggravate lipid accumulation in
hepatocytes [18]. The most promising candidate site in which
disruption of JNK-1 could largely reflect the lean phenotype of
JNK-1 knock out mice was recently identified as the central
nervous system. We and others could show, that neuronal and
pituitary JNK-1 deficiency has significant impact on insulin
sensitivity and the growth hormone/insulin like growth factor
axis [19,20]. Mice carrying a central JNK-1 inactivation were
small sized and had reduced body weight accompanied with
increased insulin sensitivity compared to controls [19].
However, none of these mouse mutants completely phe-
nocopied the effect observed in conventional JNK-1 knock out
mice indicating that other cell types or combinations thereof are
involved in mediating JNK-19s effect on insulin sensitivity.
Despite the current cell type-specific knowledge about JNK-1
signaling in the development of obesity-induced insulin resis-
tance, mimicry of JNK-1 overactivation as present in the course
of obesity has not been elucidated yet. Here, we investigated
mice with isolated transgenic overactivation of JNK-1 in skeletal
muscle for alterations in glucose metabolism and energy
homeostasis. However, besides cell type-specific aggravation of
JNK-1 signaling in these organs, the impact on insulin
sensitivity and glucose homeostasis was minor. To further
investigate the cell type specific function of JNK-1 in obesity,
we have generated conditional JNK-1 knock out mice in skeletal
muscle. Strikingly, when exposed to high fat diet, obesity
developed to a similar extent in JNK-1 mutants and controls
and obesity induced a similar inhibition of insulin action in
controls and mutants despite successful reduction of JNK-1
expression in these tissues. Taken together our data reveal, that
JNK-1 action in skeletal muscle fails to affect the development
of obesity and obesity-associated insulin resistance.
Materials and Methods
Animal Care
Care of all animals was within institutional animal care
committee guidelines. All animal procedures were conducted in
compliance with protocols and approved by local government
authorities (Bezirksregierung Ko¨ln, Cologne, Germany). Animals
were fed either normal chow diet (NCD) (2918 Teklad Global
18% Protein Rodent Diet, Teklad Diets, Madison, Wi., USA)
containing 53.5% carbohydrates, 18.5% protein, and 5.5% fat
(12% of calories from fat), or a high-fat diet (HFD) (C1057;
Altromin, Lage, Germany) containing 32.7% carbohydrates, 20%
protein, and 35.5% fat (55.2% of calories from fat) starting from 3
weeks of age. All animals had access to water and food ad libitum.
Body weight was measured once per week. Food intake was
quantified daily over a period of 7 days. Mice were sacrificed using
CO2.
Generation of JNKSM-C Mice
The JNKC construct consisting of a JNKK-2D(MKK-7D)-JNK-
1 fusion protein was created by conventional cloning techniques.
Sequences encoding the JNKK2(MKK7)-JNK1 fusion protein
[36] or a constitutively active MKK7D [37] were subcloned into
pBluescript flanked by AscI sites. The fragment containing the
S271D and T275D mutations was then excised by NotI-BsmBI
from the MKK7D containing plasmid and cloned NotI-BsmBI
into the JNKK2(MKK7)-JNK1 containing plasmid, yielding a
MKK7D-JNK1 containing plasmid. The MKK7D-JNK1 (JNKC)
sequences were then inserted into the AscI site of the STOP-
EGFP-ROSA targeting vector that additionally contained a CAG
promoter. Sequences are available upon request. 107 Bruce4 ES
cells were transfected with the targeting vector and positive clones
were identified using the ROSA probe [38] in Southern Blot
analysis. Positive ES cell clones were used to generate the ROSA
JNKC mouse strain, which was further crossed to Mck-Cre mice to
generate JNKSM-C mice. JNKSM-C mice were genotyped for the
presence of the JNKC construct by performing PCR analysis using
primers 5_MKK7_JNK1CA (59-AAG-AAC-TGC-AAG-ACG-
GAC-TT-39) and 3_MKK7_JNK1CA (59- TTC-ATA-AGA-
ACT-AGC-TCT-CTG-T-39).
Generation of JNK-1SM-KO and JNK-1KO Mice
To generate JNK-1SM-KO male mice Mck-Cre mice [21] were
crossed to JNK-1FL/FL mice [19]. Further, JNK-1FL/FL mice were
crossed to deleter Cre mice to yield JNK-1KO mice. In all
experiments, littermates carrying the loxP-flanked JNK-1 allele
were used as controls. Genotyping for the Mck-Cre trangene was
performed by PCR by using primers mck5 (59-GTT-CTT-AAG-
TCT-GAA-CCC-GG-39), mck3 (59-GTC-TGG-ATG-ACA-
TCG-TCC-AG-39) and Cre_intern_rev3 (59-ATG-TTT-AGC-
TGG-CCC-AAA-TGT-39). For identifying the JNK-1FL/FL and
the JNK-1KO alleles, the primers 5J1loxNT (59-ACA-TGT-ACC-
ATG-TAC-TGA-CCT-AAG-39), 3J1loxNT (59-CAT-TAC-TCT-
ACT-CAC-TAT-AGT-AAC-39) and 3J1deltaNT (59-GAT-ATC-
AGT-ATA-TGT-CCT-TAT-AG-39) were used.
Analysis of Body Composition
Lean mass and body fat content of live animals was determined
using the NMR Analyser Minispec (Bruker Optik).
Indirect Calorimetry
Indirect calorimetry was measured in a PhenoMaster System
(TSE Systems) as previously described [22,23]. After an overnight
acclimatization, parameters of indirect calorimetry were measured
for 48 to 72 h.
Glucose and Insulin Tolerance Test
Glucose-tolerance tests were performed on animals fasted for
16 h. Animals were injected with either 2 g/kg body weight of
glucose or 0.75 units/kg body weight of insulin (Insuman Rapid,
Sanofi Aventis) into the peritoneal cavity. Blood glucose concen-
trations were determined by using an automated glucose monitor
(GlucoMen) for the indicated time points.
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Insulin and Leptin Determination from Serum
Plasma insulin and leptin concentrations were examined by
ELISA (mouse/rat insulin ELISA, #INSKR020, mouse leptin
ELISA, #900-019, Chrystal Chem, BD Bioscience PharMingen)
according to the manufacturer’s protocol.
Southern Blot Analysis
For Southern blot, 15 mg of DNA isolated from embryonic stem
cells was digested over night with 100 U of EcoRI. The DNA
fragments were separated by agarose gel electrophoresis and
transferred onto Hybond-XLTM- membranes (Amersham) by
alkaline capillary transfer. 80 ng DNA of the ROSA26 probe
was radioactively labeled with 2.5 mCi[a32P]dATP (Amersham)
using the LaddermanTM Labeling Kit (Takara) as previously
described [24].
Gene Expression Analysis
Quantitative expression for JNKC mRNA (Hs01548508_m1,
Applied Biosystems, Foster City, USA) was determined by using
whole-muscle RNA isolated by TRIzol (Invitrogen). RNA was
reversely transcribed with High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems) and amplified by using TaqMan
Gene Expression Master Mix (Applied Biosystems). Relative
expression of mRNAs was determined by using standard curves
based on cDNA derived from the respective tissues, and samples
were adjusted for total RNA content by Hprt1
(Mm00446968_m1, Applied Biosystems), Gusb
(Mm00446953_m1, Applied Biosystems) and Tfrc
(Mm00441941_m1, Applied Biosystems) quantitative PCR. Cal-
culations were performed by a comparative cycle threshold (Ct)
method: starting copy number of test samples was determined in
comparison with the known copy number of the calibrator sample
(ddCt). The relative gene copy number was calculated as 2-ddCt.
Quantitative PCR was performed on an ABI PRISM 7900
Sequence Detector (Applied Bioscience). Assays were linear .4
orders of magnitudes.
Insulin Signaling
Mice were anesthetized by intraperitoneal injection of ketamin
(100 mg/ml, Albrecht GmbH, Germany). 5 mU of human regular
insulin (Insuman Rapid, Sanofi Aventis) were injected into the
inferior vena cava. Skeletal muscle and liver were collected 2, 5 and
7 min after injection and processed as previously described [21].
Western Blot Analysis
Muscle and liver tissues were homogenized with a polytron
homogenizer (IKA Werke) in protein lysis buffer and centrifuged
at 13,000 g for 1 h at 4uC. Proteins in the supernatant were
electrophoresed by SDS–polyacrylamide gel electrophoresis (10%)
and transferred to PVDF membranes (Bio-Rad). Membranes were
probed with the following antibodies: JNK 1/3 (Santa Cruz
Biotechnology Inc.), phospho-JNK (#4668, Cell Signaling Tech-
nology Inc.), AKT (pan) (#4685, Cell Signaling Technology Inc.),
phospho-AKT (#9271, Cell Signaling Technology Inc.), Calnexin
(#20880, Calbiochem, Germany) and goat anti-rabbit conjugated
to HRP (A6154, Sigma-Aldrich).
JNK Activity Assays
JNK activity assays were performed as previously described
[25]. Human cJun peptide (residues 1–79) fused to glutathione S-
transferase (Biovision, USA) was bound to glutathione sepharose
beads 4B (GE Healthcare, Germany) overnight. After 2 washing
steps, skeletal muscle lysates from WT and JNKSM-C mice were
incubated overnight with the GST-c-Jun fusion beads. Kinase
reaction was induced by adding 200 mM [c-32 P]-ATP (3000 Ci/
mmol) (Hartmann Analytic, Germany). After SDS-PAGE, phos-
phorylation of c-Jun was detected by using a Typhoon Trio
Imager (GE Healthcare, Germany).
Statistical Analyses
Datasets were analyzed for statistical significance by using a
two-tailed, unpaired Student’s t test and one-or two-way analysis
of variance (ANOVA) (PASW Statistics 18.0). P values,0.05 were
considered significant. For visual clarity, instead of standard
deviations, means +/2 standard errors of the mean (SEM) are
depicted in all figures.
Results
JNK is Activated in Skeletal Muscle of Obese Mouse
Models
Obesity-induced JNK activation has been described to result in
the development of insulin resistance in various organs by
inhibitory serine phosphorylation of IRS proteins [12]. In detail,
inflammatory cytokines that are elevated during the course of
obesity such as TNF-a activate upstream kinases of JNK that
phosphorylate JNK-1 and JNK-2 at specific Thr and Tyr residues
resulting in JNK activation that can be monitored by several
means. To address whether JNK is activated in response to obesity
in skeletal muscle, we examined phosphorylation of JNK by using
phospho-specific antibodies. Consistent with previous reports,
JNK phosphorylation was increased in the muscle of mice that
were exposed to high fat diet (HFD) feeding for 14 weeks when
compared to organs of mice receiving normal chow diet (NCD)
(Fig. 1A). Moreover, to quantify this increase in JNK activity and
to prove that the elevated JNK activation under HFD conditions
translates also into further downstream signaling, we elucidated
JNK activity by a kinase assay using GST coupled cJun peptide as
a substrate in lysates obtained from skeletal muscle of NCD- and
HFD-fed mice (Fig. 1B). This analysis revealed a significant
increase of JNK activity in skeletal muscle when mice were
exposed to HFD feeding as revealed by quantitation of radioac-
tively labeled cJun peptide (Fig. 1C). Thus, our data reveal a 2.8-
fold increased JNK activation in skeletal muscle under obese
conditions when compared to lean mice.
Successful Transgenic Mimicking of Diet-induced JNK-
activation in Skeletal Muscle
Obesity-induced JNK activation has been closely linked to
result in the development of insulin resistance. To mimic such
JNK overactivation, we employed a novel mouse model
allowing for Cre-activatable cell type-specific overactivation of
JNK signaling. To this end, we generated mice carrying a
constitutive active version of JNK (JNKC) in the ROSA26 locus
(ROSA JNKC), by targeted insertion of a MKK-7D-JNK-1
fusion-gene, whose expression is prevented by a loxP-flanked
transcriptional stop cassette (Fig. 1D). Upon Cre-mediated
recombination, the stop cassette is excised, thus permitting the
compound expression of the JNKC construct and EGFP. The
correct integration of the JNKC transgene into the ROSA26
locus of C57BL6-derived Bruce-4 embryonic stem cells was
confirmed by Southern blot analysis using the external ROSA26
probe (Fig. 1E). Correctly targeted ES cell clones were used to
generate the conditional ROSA JNKC mouse strain on a pure
C57/BL6 background. By crossing the ROSA JNKC to Mck-
Cre mice, we created a mouse model with isolated skeletal
muscle-specific overactivation of JNK signaling (JNKSM-C).
Transgenic JNK-1 Modulation in Skeletal Muscle
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Figure 1. Muscle specific JNK overactivation. (A) Western Blot analysis (IB) of protein lysates isolated from muscles of WT mice at 20 weeks of
age when exposed to NCD and HFD using P-JNK and JNK antibodies. (B) JNK-kinase assay of protein lysates isolated from muscles of WT mice at 20
weeks of age when exposed to NCD and HFD. Calnexin antibodies were used for input control. (C) Quantitation of radioactively labeled cJun peptide
Transgenic JNK-1 Modulation in Skeletal Muscle
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Indeed, assessment of JNK expression in skeletal muscle
revealed not only successful overexpression of the JNKC
construct on the RNA level (Fig. 1F), but also on the protein
level (Fig. 1G). Of note, to exclude transcriptional regulation of
the housekeeping gene by JNK, we compared and normalized
relative JNK expression to the expression of Hprt1, Gusb and
Tfrc genes, respectively (Fig. 1F). Nevertheless, JNKC expression
was detected exclusively in skeletal muscle but not in liver and
WAT of JNKSM-C mice confirming the skeletal muscle specific
excision of the loxP-flanked stop cassette by the Mck-Cre
transgene (Fig. 1H). The presence of the JNKC construct in
these cells clearly over-activated JNK signaling compared to
NCD-fed animals as revealed by increased phosphorylation of
the downstream target cJun in a kinase assay of skeletal muscle
lysates whereas the transgenic JNK activity reached similar
activation as detected in skeletal muscle of HFD-fed animals
(Fig. 1I, J). Importantly, to exclude variation of transgenic JNKC
overactivation in skeletal muscle of individual JNK SM-C mice,
the densitometric quantitation of phosphorylated cJun and
subsequent statistical analysis revealed similar distribution of P-
cJun levels in this group (Fig. S1A, B and Fig. 1I, J). Taken
together, we demonstrated that isolated JNKC expression in
skeletal muscle results in cell type-specific downstream JNK
overactivation as present during the course of obesity.
Isolated JNK Overactivation in Skeletal Muscle Fails to
Affect Body Composition and Energy Homeostasis
Next, we aimed to address whether JNKC expression in skeletal
muscle affects weight gain by comparing body weight of control
and JNKSM-C mice from 3 to 17 weeks of age. Body weight
measurements in cohorts of control and JNKSM-C mice revealed
that skeletal muscle-specific JNKC expression failed to affect body
weight gain over this time frame when compared to controls
(Fig. 2A). Moreover, body length was unaltered in the mutant mice
compared to controls at the age of 17 weeks (Fig. 2B). The result of
equal weighty and sized JNKSM-C and control mice was also
confirmed by a comparable abundance of body fat as revealed by
nuclear resonance spectroscopy analysis (Fig. 2C). In line with
these results, mass of epigonadal fat pads of JNKSM-C mice were
comparable to control fat pads (Fig. 2D), which in turn translated
into equal circulating amounts of the adipose-derived hormone
leptin in both cohorts of mice (Fig. 2E). Though body composition
was unaltered between control and JNKSM-C mice, we conducted
indirect calorimetry experiments of control and JNKSM-C mice to
exclude any alteration in food ingestion or energy homeostasis. In
line with unaltered body weight and fat mass, daily food intake
(Fig. 2F), energy expenditure (Fig. 2G) and respective respiratory
exchange ratio (RER) (Fig. 2H) was unchanged in the two cohorts
of mice. Collectively, these results demonstrate that JNK over-
activation in skeletal muscle fails to affect body composition and
energy expenditure.
Overactivation of JNK in Skeletal Muscle Fails to Impair
Insulin Signaling and Glucose Homeostasis in vivo
In light of the apparent lack of a major effect of skeletal muscle-
specific JNK overactivation on body composition and energy
expenditure, we wanted to address, whether isolated overactiva-
tion of JNK-dependent signaling in skeletal muscle (i.) causes
overall alteration in whole body glucose homeostasis and (ii.) can
impair insulin signaling in this organ in vivo. To this end, we
performed glucose and insulin tolerance tests as well as examined
circulating insulin concentrations and insulin-stimulated AKT
phosphorylation as a measure of insulin sensitivity. Time-
dependent glucose clearance from the blood upon intraperitoneal
glucose challenge was identical between control and JNKSM-C
mice in glucose tolerance tests (Fig. 3A). Additionally, insulin
sensitivity was unchanged in insulin tolerance tests in the two
cohorts of mice (Fig. 3B). Moreover, circulating insulin concen-
trations were not affected by skeletal muscle specific JNK
overactivation (Fig. 3C). Consistent with these observations,
analysis of insulin-stimulated AKT-phosphorylation in skeletal
muscle and liver of control and JNKSM-C mice revealed that JNK
overactivation in skeletal muscle did neither affect insulin-
stimulated AKT-activation in muscle nor in liver (Fig. 3D). Taken
together, these data indicate that overactivated JNK signaling in
skeletal muscle as present during the course of obesity fails to
impair whole body glucose homeostasis and insulin-stimulated
signaling events in vivo.
Unaltered Energy Homeostasis and Body Composition in
Mice Lacking JNK-1 in Skeletal Muscle
The previously published analysis of conventional JNK-1 knock
out mice had revealed, that these animals are not only protected
from obesity-associated insulin resistance, but that they also exhibit
reduced weight gain, both after exposure to high fat diet (HFD) as
well as on the background of the ob/ob genetic obesity model [12].
To directly address whether skeletal muscle specific disruption of
JNK-1 contributes to this effect, we investigated our recently
described mice with skeletal muscle specific disruption of JNK-1
(JNK-1SM-KO mice) [26]. To this end, we exposed cohorts of
control and JNK-1SM-KO mice to normal chow (NCD) and high
fat diet (HFD) conditions starting from 3 weeks of age and
monitored parameters of adiposity as well as energy homeostasis in
these animals. Though this analysis revealed that HFD-exposure
significantly increased body weight, body length, body fat content,
epididymal fat pad mass as well as circulating plasma leptin
concentrations in control mice exposed to HFD compared to those
exposed to NCD (Fig. 4A, B, C, D, E), parameters of mice with
skeletal muscle specific JNK-1 deficiency were indistinguishable
from control mice, both under NCD and HFD conditions.
Accordingly, while unaltered food intake and energy expenditure
between control and JNK-1SM-KO mice was demonstrated
previously [26], also food intake and energy expenditure as well
as respective respiratory exchange ratios were indistinguishable
in skeletal muscle of NCD fed WT and HFD WT mice. (D) Targeting strategy for the Cre-activatable JNKC construct into the ubiquitously expressed
ROSA26 locus. The CAG modified STOP-EGFP-ROSA targeting vector was described elsewhere. In the unique AscI site, a fusion cDNA between the
mutant MKK7D [36] and JNK-1 [37] was inserted to generate the final ROSA JNKC targeting vector. Homologous recombination between the
homology arms and the genomic ROSA26 locus generated the targeted allele which was identified by Southern Blot analysis of EcoRI-digested clonal
DNA using the ROSA probe [38] resulting in the 16 kb WT band besides the 6 kb targeted band as shown in (E). Such positive C57/BL6-derived ES cell
clones were used to generate the ROSA JNKC mouse strain. (F) Determination of relative JNK-1 mRNA expression in skeletal muscle of WT and JNKSM-C
mice by quantitative realtime PCR using Hprt1, Gusb and Tfrc as housekeeping genes (n = 8). (G) Western Blot analysis of protein lysates isolated from
skeletal muscle of WT and JNKSM-C mice using JNK-1 and AKT antibodies. (H) Expression of the JNKC fusion protein only in skeletal muscle of JNKSM-C
mice indicated by Western blot analysis. (I) Functionality of the JNKC construct in skeletal muscle of JNKSM-C mice was revealed by increased
phosphorylation of cJun in JNK kinase assay (KA) experiments. (J) Quantitation of radioactively labeled cJun peptide in skeletal muscle of NCD fed WT,
JNKSM-C and HFD WT mice. Values are means 6 SEM. ***, p#0.001.
doi:10.1371/journal.pone.0054247.g001
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between JNK-1SM-KO and control mice under obese conditions
(Fig. 4F, G, H). In summary, our results clearly indicate that
skeletal muscle-specific disruption of JNK-1 fails to affect body
composition and energy homeostasis in lean and obese mice
indicating that JNK-1-dependent signaling in other organs than
skeletal muscle accounts for the protective effect of JNK-1
deficiency against the development of diet-induced obesity.
Lack of JNK-1 in Skeletal Muscle does not Affect Glucose
Homeostasis and Insulin Sensitivity Under Normal and
Obese Conditions
While JNK-1-deficiency in skeletal muscle did not affect the
development of HFD-induced obesity, we next aimed to analyze,
whether the absence of JNK-1-signaling in this organ affects the
manifestation of obesity-associated insulin resistance. Exposure to
HFD led to significantly impaired glucose and insulin tolerance in
control mice compared to the NCD fed control cohort (Fig. 5A, B).
However, when compared to the control groups of mice, glucose
and insulin tolerance was unaltered in JNK-1SM-KO mice both
under lean and obese conditions (Fig. 5A, B). Moreover, while
plasma insulin concentrations were significantly increased in obese
control mice compared to NCD from 5 ng/ml to 25 ng/ml,
identical results were obtained from mice with muscle specific
JNK-1 deficiency (Fig. 5C). Thus, JNK-1-deficiency in skeletal
muscle does not result in significant improvements of diet-induced
deterioration of glucose metabolism in mice.
Figure 2. Unaltered body composition and energy homeostasis in JNKSM-C mice. (A) The average bodyweight of control (open squares)
mice was compared with JNKSM-C (grey squares) mice from 3 to 17 weeks of age when feeding a NCD (n= 15). (B) Body length of control (white bar)
and JNKSM-C (grey bar) mice upon NCD feeding (n = 9–12). (C) Body composition of control (white bar) and JNKSM-C (grey bar) mice when exposed to
NCD was determined by using a Brucker minispec in week 17 (n = 10–12). (D) Weight of epigonadal fat pads from NCD fed control (white bar) and
JNKSM-C (grey bar) mice in week 17 (n = 9). (E) Serum leptin levels of control (white bar) and JNKSM-C (grey bar) mice at the age of 17 weeks (n = 9). (F)
Daily food intake of control (white bar) and JNKSM-C (grey bar) mice upon NCD feeding at the age of 14 weeks (n = 5). (G) Energy expenditure revealed
by the daily and nightly volume of O2 consumption and CO2 release of control (white bar) and JNK
SM-C (grey bar) mice upon NCD feeding (n = 5). (H)
Respiratory exchange rate (RER) of control (white bar) and JNKSM-C (grey bar) mice upon NCD feeding (n = 5). Values are means 6 SEM.
doi:10.1371/journal.pone.0054247.g002
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In the absence of alterations of whole body glucose metabolism
in JNK-1SM-KO mice compared to control mice, we next wanted
to address, whether lack of JNK-1 in these organs may still lead to
improved insulin signal transduction at a molecular level, which
possibly fails to translate to changes in overall glucose metabolism.
Thus, we assessed insulin’s ability to stimulate phosphorylation of
AKT, as a measure for insulin-stimulated AKT activation in vivo.
This analysis revealed impaired insulin-stimulated AKT-phos-
phorylation both in skeletal muscle and liver (Fig. 5D) of control
mice exposed to HFD compared to lean controls exposed to NCD.
However, the lack of JNK-1 in skeletal muscle could not improve
the diet-induced inhibition of insulin-stimulated AKT-phosphor-
ylation in these organs (Fig. 5D). Thus, our experiments
unequivocally demonstrate, that JNK-1 is dispensable for the
development of diet-induced insulin resistance in skeletal muscle of
mice.
Noteworthy, our data are not in line with a previous report that
identified a role of skeletal muscle specific JNK-1 in the
development of diet-induced local and systemic insulin resistance
(17). To assess whether this discrepancy might be a consequence of
an alternative physiological characterization, we investigated
control C57/BL6 mice in the different phenotyping protocols.
To this end, cohorts of C57/BL6 mice were exposed to NCD and
HFD starting with 3 weeks of age (WTS3), and compared to
cohorts of C57/BL6 mice receiving the different diets with 8 weeks
of age (WTS8), respectively. This analysis demonstrated that HFD
exposure increased bodyweight gain, body length as well as
adiposity in both protocols to a similar extent when compared to
the NCD exposed control mice (Fig. S2A, B, C, D). The similar
adiposity of WTS3 and WTS8 control mice exposed to HFD
feeding could also be confirmed by the presence of similar
circulating leptin levels as revealed by ELISA (Fig. S2E).
Furthermore, while indirect calorimetry experiments revealed that
WTS3 mice showed increased VO2 consumption and VCO2
production compared to the WTS8 counterparts mainly during
the day phase under both dietary conditions, the respiratory
exchange rate resulting from these data was indistinguishable (Fig.
S2F, G). Nevertheless, diet-induced impairments of glucose
homeostasis were similar in both protocols as revealed by glucose
tolerance and insulin tolerance tests as well as increased circulating
insulin concentrations (Fig. S2H, I, J, K, L). Collectively, these
data demonstrate that the discrepancy between the previously
published work (17) and our study is not a result of different
physiological characterization protocols.
Bodywide JNK-1 Deficiency Protects against HFD-
induced Glucose Intolerance and Insulin Resistance
Disruption of JNK-1 by conventional means results in decreased
obesity and improved glucose metabolism [12]. To confirm this
important finding with our JNK-1 allele, we inactivated JNK-1 in
the whole body by crossing JNK-1FL/FL mice to deleter Cre mice
Figure 3. Unaltered glucose metabolism and insulin sensitivity in JNKSM-C mice. (A) Glucose tolerance tests of control (white bar) and
JNKSM-C (grey bar) mice when feeding a NCD were performed at 11 weeks of age (n = 10–13). (B) Insulin tolerance tests of control (white bar) and
JNKSM-C (grey bar) mice upon NCD feeding were performed at 12 weeks of age (n = 13–15). (C) Insulin levels from sera isolated at week 17 from mice
with the indicated genotypes upon NCD feeding determined by ELISA (n = 8–10). (D) Representative insulin-induced AKT phosphorylation of muscle
and liver lysates isolated from control and JNKSM-C mice when feeding NCD using Western Blot analysis with the indicated antibodies. Values are
means 6 SEM.
doi:10.1371/journal.pone.0054247.g003
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(JNK-1KO mice). Consistent with previously published results,
JNK-1KO mice on a NCD show not only unaltered bodyweight
but also similar naso-anal lengths at 17 weeks of age when
compared to controls (Fig. S3A, B). In line with these data,
adiposity and epigonadal fat pad weights as well as circulating
leptin levels and food ingestion were comparable between the two
groups of mice (Fig. S3C, D, E, F). Moreover, while the
parameters of energy homeostasis matched between control and
JNK-1KO mice (Fig. S3G, H), glucose tolerance and insulin
sensitivity were largely unaffected by complete JNK-1 deficiency
under normal conditions (Fig. S3I, J, K). As the beneficial effects of
JNK-1 deficiency were observed under obese conditions, we
assessed energy and glucose homeostasis in JNK-1KO and control
mice also when exposed to HFD feeding. Indeed, determination of
body weight from weaning until 17 weeks of age of WT and JNK-
1KO mice revealed that JNK-1KO mice are protected from HFD-
induced weight gain (Fig. 6A). Moreover, since mice lacking JNK-
1 in the CNS show a reduction in somatic growth as a
consequence of impaired growth hormone/insulin like growth
factor 1 axis [19], body length of WT and JNK-1KO mice was
assessed, revealing a significant reduction of body length in JNK-
1KO mice fed a HFD (Fig. 6B). The degree of adiposity in WT and
JNK-1KO mice upon HFD feeding was determined by NMR
analysis and by measuring the weight of the epigonadal fat pads.
These analyses demonstrated that JNK-1KO mice exhibit
decreased body fat content when compared to WT mice as well
Figure 4. Unaltered body composition and energy homeostasis in JNK-1SM-KO mice under normal and obese conditions. (A) The
average bodyweight of control NCD fed (open circles) and HFD fed (open squares) mice was compared with JNK-1SM-KO mice fed a NCD (black circles)
or a HFD (black squares) from 3 to 17 weeks of age (n = 15–45). (B) Body length of control (white bar) and JNK-1SM-KO (black bar) mice upon NCD and
HFD feeding. (C) Body composition of control (white bar) and JNK-1SM-KO (black bar) mice when exposed to NCD or HFD were determined by using a
Brucker minispec in week 17 (n = 11–24). (D) Weight of epigonadal fat pads from NCD and HFD fed control (white bar) and JNK-1SM-KO (black bar)
mice in week 17 (n = 13–40). (E) Serum leptin levels of control (white bar) and JNK-1SM-KO (black bar) mice upon NCD and HFD feeding at the age of 17
weeks (n = 8–18). (F) Daily food intake of control (white bar) and JNK-1SM-KO (black bar) mice upon HFD feeding at the age of 14 weeks (n = 5–27). (G)
Energy expenditure revealed by the daily and nightly volume of O2 consumption and CO2 release of control (white bar) and JNK-1
SM-KO (black bar)
mice upon HFD feeding (n = 8). (H) Respiratory exchange rate (RER) of control (white bar) and JNK-1SM-KO (black bar) mice upon HFD feeding (n = 8).
Values are means 6 SEM. **, p#0.01; ***, p#0.001.
doi:10.1371/journal.pone.0054247.g004
Transgenic JNK-1 Modulation in Skeletal Muscle
PLOS ONE | www.plosone.org 8 January 2013 | Volume 8 | Issue 1 | e54247
as reduced epigonadal fat pad weight (Fig. 6 C and D). Consistent
with these findings, serum levels of leptin as an indirect measure of
adiposity were reduced in JNK-1KO mice when compared to WT
mice (Fig. 6 E). Collectively, these results demonstrate that mice
lacking JNK-1 in the whole body are protected from the
development of HFD-induced adiposity. Reduced adiposity
develops either in light of a reduced caloric intake or due to
increases in energy expenditure or both. Noteworthy, the
decreased adiposity of JNK-1KO mice is a consequence of
significantly reduced food intake of JNK-1KO mice compared to
controls (Fig. 6 F) rather than increased energy expenditure, whose
means were only minor affected (Fig. 6 G). However, JNK-1KO
mice showed reduced HFD-induced lipid utilization as the daily
and nightly RER was increased compared to controls (Fig. 6 H).
Next, we wanted to address whether the reduction in adiposity in
JNK-1KO mice under obese conditions translates into improved
glucose homeostasis. Hence, glucose and insulin tolerance tests
were performed. This analysis revealed that the time-dependent
glucose clearance from the blood upon an intraperitoneal glucose
challenge was markedly ameliorated in JNK-1KO mice when
compared to control mice fed a HFD (Fig. 6 I). Moreover, insulin
sensitivity as assessed by an insulin tolerance was strongly
improved in JNK-1KO mice when compared to WT mice (Fig. 6
J). Strikingly, JNK-1KO mice were also protected from HFD-
induced hyperinsulinemia as indicated by reduced circulating
levels of insulin in comparison to WT mice (Fig. 6 K). In summary,
these results clearly support previous work indicating that body-
wide JNK-1 deficiency protects from diet-induced weight gain and
insulin resistance. Thus, our experiments assign JNK-1 activation
in tissues other than skeletal muscle a critical role in the
development of obesity-associated deterioration of energy and
glucose homeostasis.
Discussion
The notion that obesity is associated with an increased
inflammatory state, which activates numerous intracellular signal-
ing cascades in turn inhibiting insulin action provides a unique
opportunity for the development of novel therapeutic interventions
to treat obesity-associated insulin resistance and diabetes. Howev-
er, these novel therapeutic approaches require the exact definition
of the intracellular signaling cascade activated by cytokines such as
TNF-a and IL-6, ER-stress or altered lipid composition contrib-
uting to the inhibition of insulin signaling in a tissue-specific
manner. Here, numerous candidate pathways activated by these
stimuli have been shown to cause inhibitory serine phosphoryla-
tion of insulin receptor substrate proteins or to induce insulin
resistance by other mechanisms [3,4,7,8].
Thus, obesity-induced inflammatory signaling pathways include
activation of IkBa kinases (IKK), the c-Jun N-terminal kinases
(JNK), atypical protein kinase C (PKC) and it has been recently
recognized that altered diacylglycerol (DAG) content in skeletal
Figure 5. Unaltered glucose metabolism and insulin sensitivity in JNK-1SM-KO under normal and obese conditions. (A) Glucose
tolerance tests of control NCD fed (open circles) and HFD fed (open squares) mice and JNK-1SM-KO mice fed a NCD (black circles) or a HFD (black
squares) were performed at 11 weeks of age (n = 9–49). (B) Insulin tolerance tests of control NCD fed (open circles) and HFD fed (open squares) mice
and JNK-1SM-KO fed a NCD (black circles) or a HFD (black squares) were performed at 12 weeks of age (n = 5–30). (C) Insulin levels from sera isolated at
week 17 from mice with the indicated genotypes upon NCD or HFD feeding determined by ELISA (n = 5–9). (D) Representative insulin-induced AKT
phosphorylation of muscle and liver lysates isolated from control and JNK-1SM-KO mice when feeding NCD and HFD using Western Blot analysis with
the indicated antibodies. Values are means 6 SEM. **, p#0.01; ***, p#0.001.
doi:10.1371/journal.pone.0054247.g005
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muscle can induce insulin resistance via diacylglycerol kinase
(DGK) activation [27].
We and others could demonstrate that in liver, IKK activation
plays an important function in the development of obesity-
associated insulin resistance and that both, liver-specific IKK-2 or
NEMO deficiency can protect from obesity-associated impairment
of glucose tolerance [24,28]. However, deletion of IKK-2 in
skeletal muscle fails to prevent the development of obesity-
associated insulin resistance, underlining the tissue-specific contri-
bution of inflammatory mediators to cause insulin resistance [29].
Figure 6. Complete absence of JNK-1 protects from HFD-induced obesity and insulin resistance. (A) The average body weight of WT
(white diamonds) and JNK-1KO (black diamonds) mice fed a HFD from 3 to 17 weeks of age (n = 12–18). (B) Body length of WT and JNK-1KO mice upon
HFD at 17 weeks age (n = 15). (C) Body composition of WT (white bar) and JNK-1KO (black bar) mice when exposed to HFD was determined by using a
Brucker minispec in week 17 (n = 15–19). (D) Weight of epigonadal fat pads from HFD fed WT (white bar) and JNK-1KO (black bar) mice in week 17
(n = 10–12). (E) Serum leptin levels of WT (white bar) and JNK-1KO (black bar) mice at the age of 17 weeks (n = 10). (F) Daily food intake of WT (white
bar) and JNK-1KO (black bar) mice upon HFD feeding at the age of 14 weeks (n = 17). (G) Energy expenditure revealed by the daily and nightly volume
of O2 consumption and CO2 release of WT (white bar) and JNK-1
KO (black bar) mice upon HFD feeding (n = 5). (H) Respiratory exchange rate (RER) of
control (white bar) and JNK-1KO (black bar) mice upon HFD feeding (n = 5). (I) Glucose tolerance tests of WT (white diamonds) and JNK-1KO (black
diamonds) mice when feeding a HFD were performed at 11 weeks of age (n = 14). (J) Insulin tolerance tests of WT (white diamonds) and JNK-1KO
(black diamonds) mice upon HFD feeding were performed at 12 weeks of age (n = 14) (K) Insulin levels from sera isolated at week 17 from mice with
the indicated genotypes upon HFD feeding determined by ELISA (n = 8). Values are means 6 SEM, *, p,0.05, **, p,0.01, ***, p,0.001.
doi:10.1371/journal.pone.0054247.g006
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In light of the dramatic protection from the occurrence of
obesity-associated insulin resistance in conventional JNK-1-, but
not JNK-2-deficient animals, JNK-1 was predicted to play an
important role - particularly in the insulin-sensitive target tissue
skeletal muscle - to cause obesity-associated insulin resistance [12].
Here we demonstrate what was also reported by others that
obesity increases JNK activation in skeletal muscle that could
potentially impair insulin signaling accounting for the develop-
ment of obesity-associated insulin resistance in this tissue [17]. To
elucidate this possibility, we successfully generated a mouse strain
allowing for Cre-activated expression of a JNK constitutively
active construct that we crossed to Mck-Cre mice to obtain skeletal
muscle specific overactivation of JNK signaling as it is present
under obese conditions. However, our metabolic data using these
mice eliminate the assumption that increased JNK activation
under obese conditions in skeletal muscle impairs insulin signaling
but instead clearly communicate the important observation that
obesity-induced JNK activation fails to impair insulin action in this
organ. Despite similar skeletal muscle specific JNK overactivation
in these mice as it is present under obese conditions, these mice
lacked any alteration in adiposity, glucose metabolism and energy
homeostasis. In line with this observation, we also characterized
mice with isolated JNK-1 deficiency in skeletal muscle under lean
and obese conditions in which none of the assessed metabolic
parameters were affected. Thus, our current finding that isolated
JNK overactivation and JNK-1 deficiency in skeletal muscle fails
to protect from obesity-associated disturbances in overall glucose
metabolism as assessed during glucose tolerance and insulin
tolerance tests is surprising. Several explanations may account for
this phenomenon. An obvious possibility would be redundant
signaling functions of other JNK isoforms in the absence of JNK-1.
Therefore, in skeletal muscle, JNK-2 activation may compensate
for the lack of JNK-1 and thereby cause development of insulin
resistance upon obesity-induction. Indeed, it could be demon-
strated that compound deficiency for JNK-1 and heterozygousity
for a conventional JNK-2 null allele has a more profound effect to
protect from diet-induced insulin resistance than isolated JNK-1
deficiency [13]. Thus, in skeletal muscle either JNK-1 and JNK-2
contribute cooperatively to the development of obesity-associated
insulin resistance or alternative kinases such as atypical PKC- and
DGK-activation may play a more important role in the
development of obesity-induced insulin resistance in this organ
[27,30]. An alternative explanation that in our settings JNK-1
deficiency in skeletal muscle fails to improve obesity-associated
disorders might be the diverging gene targeting strategies used by
us and others [17,19]. Though the previously described JNK-1
conventional knock out mouse replaces exon 2 of JNK-1 with a
neo resistance gene [12] and we copied this strategy by flanking
exon 2 of JNK-1 with loxP sites, we assessed whether the absence
of JNK-1 in the whole body indeed protects from diet-induced
obesity and associated disorders. Consistent with the report of
Hirosoumi and colleagues [12], also our JNK-1 deficient mouse
model showed protection against the development of diet-induced
weight gain and showed improved insulin sensitivity.
Thus, what remains a striking observation requiring further
investigation is the profound difference of the metabolic phenotype
of conventional JNK-1-deficient mice and the reported pheno-
types for mice with cell type-specific disruption of JNK-1 activity.
While our report clearly demonstrates that skeletal muscle-specific
JNK-1 deficiency is not sufficient to protect against obesity-
associated insulin resistance, a recent report indicates that
inactivation of JNK-1 in the adipose tissue causes some degree
of protection from obesity-associated insulin resistance due to the
inactivation of JNK-1 in adipose tissue [7]. In the latter study,
adipocyte-autonomous JNK-1 signaling regulates IL-6 secretion in
the obese white adipose tissue that in turn inhibits hepatic insulin
action through IL-6-induced SOCS-3 expression in the liver
[31,32]. Noteworthy, we demonstrated recently that JNK-1
signaling in skeletal muscle controls IL-6 expression in response
to exercise [26] implicating an important function of JNK-1-
induced IL-6 expression also in other cell types. However, JNK-1-
deficient myeloid lineage cells show unaltered IL-6 expression and
JNK-1 deficiency in these cells per se had no effect on the
development of obesity-associated insulin resistance whereas other
reports on bone marrow transplantation chimeras with JNK-1-
deficient hematopoetic stem cells have yielded controversial
findings [14–16]. Nevertheless, neither adipocyte-specific disrup-
tion nor hematopoetic-specific JNK-1-deficiency phenocopies the
effect of conventional JNK-1 deletion. In line with these reports,
also JNK-1 deficiency in liver parenchymal cells has failed to affect
body weight gain and insulin sensitivity, but demonstrated an
important function of JNK-1 in the prevention of hepatic lipid
accumulation [18]. Another candidate organ where the absence of
JNK-1 could protect from diet-induced obesity is the central
nervous system (CNS). The CNS plays a central role in the control
of body weight and peripheral glucose metabolism [33,34]. Within
the CNS, insulin action particularly in agouti-related peptide-
expressing neurons of the arcuate nucleus of the hypothalamus
controls peripheral glucose metabolism via inhibition of hepatic
glucose production [35]. Thus, JNK-mediated inhibition of insulin
signal transduction in the CNS may play an important role in
deterioration of peripheral glucose metabolism. Essentially, we
have demonstrated that the combined inactivation of JNK-1 in the
CNS and the pituitary represents as yet the most promising
approach to resemble the phenotype of conventional JNK-1 knock
out mice [19]. Though in these mice adiposity is unaffected in
response to HFD, systemic insulin sensitivity is improved
accompanied with reduced somatic growth. Taken together, our
experiments provide evidence for an important role of JNK-1
signaling in organs other than skeletal muscle in the development
of obesity-associated insulin resistance and diabetes.
Supporting Information
Figure S1 Transgenic JNKC expression in skeletal
muscle enhances phosphorylation of cJun. (A) JNK-kinase
assay (KA) of protein lysates isolated from muscles of WT and
JNKSM-C mice fed a NCD. Calnexin antibodies were used for
input control of the lysates. (B) Quantitation of radioactively
labeled cJun peptide in skeletal muscle of NCD fed WT and
JNKSM-C mice. The data were adjusted to the WT NCD data
shown in figure 1 B, C. Values are means 6 SEM. *, p#0.05.
(TIF)
Figure S2 Physiological comparison of diet-induced
obesity protocols. (A) The average bodyweight of WTS3
NCD fed (open squares) and WTS3 HFD fed (grey circles) mice
was compared with WTS8 mice fed a NCD (open squares) or a
HFD (grey circles) from 0 to 17 weeks on both diets, respectively
(n = 10). (B) Body length of WTS3 (white bar) and WTS8 (grey
bar) mice upon NCD and HFD feeding (n = 10). (C) Body
composition of WTS3 (white bar) and WTS8 (grey bar) mice when
exposed to NCD or HFD was determined by using a Brucker
minispec in week 17 of feeding the diets (n = 10). (D) Weight of
epigonadal fat pads from NCD and HFD WTS3 (white bar) and
WTS8 (grey bar) mice in week 17 of feeding the diets (n = 10). (E)
Serum leptin levels of WTS3 (white bar) and WTS8 (grey bar)
mice upon NCD and HFD feeding after 17 weeks on both the
diets (n = 10). (F) Energy expenditure revealed by the daily and
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nightly volume of O2 consumption and CO2 release of WTS3
(white bar) and WTS8 (grey bar) mice upon NCD and HFD
feeding (n= 10). (G) Respiratory exchange rate (RER) of WTS3
(white bar) and WTS8 (grey bar) mice upon NCD and HFD
feeding (n= 10). (H) Glucose tolerance tests of WTS3 NCD fed
(open squares) and HFD fed (open circles) mice were performed
after 17 weeks on either diet (n = 10). (I) Glucose tolerance tests of
WTS8 NCD fed (grey squares) and HFD fed (grey circles) mice
were performed after 17 weeks on either diet (n = 10). (J) Insulin
tolerance tests of WTS3 NCD fed (open squares) and HFD fed
(open circles) mice were performed after 17 weeks on either diet
(n = 10). (K) Insulin tolerance tests of WTS8 fed a NCD (grey
squares) or a HFD (grey circles) were performed after 17 weeks on
either diet (n = 10). (L) Insulin levels from sera isolated after 17
weeks on either of the diets from mice with the indicated genotypes
determined by ELISA (n= 10). Values are means 6 SEM. **,
p#0.01; ***, p#0.001.
(TIF)
Figure S3 Phenotypical analysis of bodywide JNK-1
deficiency under normal conditions. (A) The average body
weight of WT (white bars) and JNK-1KO (black bars) mice fed a
NCD at 17 weeks of age (n = 5). (B) Body length of WT and JNK-
1KO mice upon NCD feeding at 17 weeks age (n = 5). (C) Body
composition of WT (white bar) and JNK-1KO (black bar) mice
when exposed to NCD was determined by using a Brucker
minispec in week 17 (n= 5). (D) Weight of epigonadal fat pads
from NCD fed WT (white bar) and JNK-1KO (black bar) mice in
week 17 (n= 5). (E) Serum leptin levels of WT (white bar) and
JNK-1KO (black bar) mice at the age of 17 weeks (n = 5). (F) Daily
food intake of WT (white bar) and JNK-1KO (black bar) mice upon
NCD feeding at the age of 14 weeks (n = 5). (G) Energy
expenditure revealed by the daily and nightly volume of O2
consumption and CO2 release of WT (white bar) and JNK-1
KO
(black bar) mice upon NCD feeding (n= 5). (H) Respiratory
exchange rate (RER) of control (white bar) and JNK-1KO(grey bar)
mice upon NCD feeding (n= 5). (I) Glucose tolerance tests of WT
(white diamonds) and JNK-1KO (black diamonds) mice when
feeding a NCD were performed at 11 weeks of age (n = 5). (J)
Insulin tolerance tests of WT (white diamonds) and JNK-1KO
(black diamonds) mice upon NCD feeding were performed at 12
weeks of age (n = 5) (K) Insulin levels from sera isolated at week 17
from mice with the indicated genotypes upon NCD feeding
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